A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes

BACKGROUND: There are several reports of seasonal variation in hemoglobin A1c (HbA1c) in patients with type 2 diabetes (T2DM), but no reports of seasonal variation in the effect of add-on drugs on blood glucose control in insulin-treated patients. METHODS: Using data collected from 630 patients in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Takai, Masahiko, Ishikawa, Masashi, Maeda, Hajime, Kubota, Akira, Iemitsu, Kotaro, Umezawa, Shinichi, Kawata, Takehiro, Takuma, Tetsuo, Takeda, Hiroshi, Tanaka, Keiji, Machimura, Hideo, Minagawa, Fuyuki, Mokubo, Atsuko, Motomiya, Tetsuya, Kanamori, Akira, Matsuba, Ikuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092762/
https://www.ncbi.nlm.nih.gov/pubmed/32231757
http://dx.doi.org/10.14740/jocmr4103
Descripción
Sumario:BACKGROUND: There are several reports of seasonal variation in hemoglobin A1c (HbA1c) in patients with type 2 diabetes (T2DM), but no reports of seasonal variation in the effect of add-on drugs on blood glucose control in insulin-treated patients. METHODS: Using data collected from 630 patients in a multicenter study, we compared the amount of change in HbA1c after 1, 3, 6, 9, and 12 months of add-on administration of sitagliptin in insulin-treated patients divided into four groups based on the month when sitagliptin was started. RESULTS: A significantly larger decrease in HbA1c at 6 months from baseline was observed in the group that started add-on sitagliptin in February to April than in the other three groups. However, the amount of change in HbA1c at 12 months did not differ among the groups. CONCLUSIONS: The consideration of seasonal variation enables more accurate evaluation of a drug’s short-term effect on blood glucose control.

Ejemplares similares